


臨床経過



7. 引用文献・参考資料

引用文献

- 1)がん化学療法の有害反応対策ハンドブック第4版. 先端医学社 2004:280.
- 2)Gressett SM, Stanford BL, Hardwicke F. Management of hand-foot syndrome induced by capecitabine. *J Oncol Pharm Pract* 2006;12:131-141.
- 3)Riechelmann RP, Chin S, Wang L, et al. Sorafenib for metastatic renal cancer: the princess margaret experience. *Am J Clin Oncol* 2008;31:182-187.
- 4)Tsai KY, Yang CH, Kuo TT, et al. Hand-foot syndrome and seborrheic dermatitis-like rash induced by sunitinib in a patient with advanced renal cell carcinoma. *J Clin Oncol* 2006;24:5786-5788.
- 5)山崎直也, 田口哲也. 五感の生理, 病理と臨床 痛覚 痛覚を含む Hand-foot syndrome 抗癌剤によって起こる知覚障害. *医学のあゆみ* 2006;216(3):257-260.
- 6)山崎直也. CapecitabineとHand-Foot Syndrome. *癌治療と宿主* 2004;16(2):137-141.
- 7)Scheithauer W, McKendrick J, Begbie S, et al. Oral capecitabine as an alternative to i.v. 5-fluorouracil-based adjuvant therapy for colon cancer: safety results of a randomized, phase III trial. *Ann Oncol* 2003;14:1735-1743.
- 8)Elasmar SA, Saad ED, Hoff PM. Case report: Hand-foot syndrome induced by the oral fluoropyrimidine S-1. *Jpn J Clin Oncol*2001;31:172-174.
- 9)Gerbrecht BM. Current Canadian experience with capecitabine: partnering with patients to optimize therapy. *Cancer Nurs* 2003;26:161-167.
- 10)下松谷匠, 光藤悠子, 中村誠昌, 他. Capecitabineによる重症手足症候群を 発症した乳癌の1例. *癌と化学療法* 2007;34:1139-1141.
- 11)Lacoutre ME, Reilly LM, Gerami P, et al. Hand foot skin reaction in cancer patients treated with the multikinase inhibitors sorafenib and sunitinib. *Ann. Oncol.* 2008, doi:10.1093/annonc/mdn389
- 12) Blum JL, Jones SE, Buzdar AU, et al. Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer. *J Clin Oncol*1999;17:485-493.
- 13) Leonard R, OShaughnessy J, Vukelja S, et al. Detailed analysis of a randomized phase III trial: can the tolerability of capecitabine plus docetaxel be improved without compromising its survival advantage? *Ann Oncol.* 2006;17(9):1379-1385.
- 14) Lee S, Lee S, Chun Y, et al. Pyridoxine is not effective for the prevention of hand foot syndrome (HFS) associated with capecitabine therapy: Results of a randomized double-blind placebo-controlled study. *J Clin Oncol* 2007;25:18S, Abstract 9007.
- 15) Lin E, Morris JS, Ayers GD. Effect of celecoxib on capecitabine-induced hand-foot syndrome and antitumor activity. *Oncology (Willistone Park)*2002;16:31-37.
- 16) Von Moos R, Thuerlimann BJ, Aapro M, et al. Pegylated liposomal doxorubicin-associated hand-foot syndrome: recommendations of an international panel of experts. *Eur J Cancer* 2008;44:781-790.

- 17) Drake RD, Lin WM, King M, et al. Oral dexamethasone attenuates Doxil- induced palmar-plantar erythrodysesthesias in patients with recurrent gynecologic malignancies. *Gynecol Oncol* 2004;94:320-324.

参考資料文献

手足症候群 Hand-foot Syndrome アトラス 田口哲也 監修 2005 中外製薬

手足症候群 Hand-foot Syndrome Atlas 田口哲也 監修 2007 中外製薬

癌治療と皮膚反応 治療中に皮膚に現れる副作用の識別とその対処のためのガイドライン Bayer薬品提供資料

- 1) Hoff PM, Ansari R, Batist G, et al. Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study. *J Clin Oncol*. 2001;19:2282-2292.
- 2) Van Cutsem E, Twelves C, Cassidy J, et al. Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study. *J Clin Oncol*. 2001;19:4097-4106.
- 3) Jonker DJ, O'Callaghan CJ, Karapetis CS, et al. Cetuximab for the treatment of colorectal cancer. *N Engl J Med*. 2007;357:2040-2048.
- 4) Lai SE, Kuzel T, Lacouture ME. Hand-foot and stump syndrome to sorafenib. *J Clin Oncol*. 2007;25:341-343.
- 5) Robert C, Soria JC, Spatz A, et al. Cutaneous side-effects of kinase inhibitors and blocking antibodies. *Lancet Oncol*. 2005;6:491-500.
- 6) Yang CH, Lin WC, Chuang CK, et al. Hand-foot skin reaction in patients treated with sorafenib: a clinicopathological study of cutaneous manifestations due to multitargeted kinase inhibitor therapy. *Br J Dermatol*. 2008;158:592-596.
- 7) Chu D, Lacouture ME, Fillos T, et al. Risk of hand-foot skin reaction with sorafenib: a systematic review and meta-analysis. *Acta Oncol*. 2008;47:176-186.
- 8) Rosenbaum SE, Wu S, Newman MA, et al. Dermatological reactions to the multitargeted tyrosine kinase inhibitor sunitinib. *Support Care Cancer* 2008;16:557-566.